Challenges in Global Medical Device Software Rules

If you sell one medical software product in both the U.S. and Europe, you usually need two rulebooks, two evidence plans, and two postmarket workflows.

That is the core problem. The FDA and EU MDR often treat the same software differently on classification, cybersecurity, clinical evidence, AI updates, and patch handling. I see the biggest friction in five places:

• Software scope: SaMD and embedded software do not land the same way in each market.
• Classification: A product that may sit in a lower class in the U.S. can move to Class IIb or III in Europe under Rule 11.
• Cybersecurity: The FDA has a defined cyber device path with items like SBOMs and threat modeling. The EU spreads security duties across MDR requirements instead.
• Evidence: The FDA may use predicate-based review, while the EU often wants a separate clinical evaluation plus PMCF.
• AI change control: The FDA now has PCCP guidance for some AI/ML updates, while Europe still splits review across EU MDR and the EU AI Act, with core high-risk AI duties starting on August 2, 2026.

Here’s the short answer: global alignment is still limited, so I would treat internal harmonization as the only working path today. That means one shared classification method, one SDLC baseline such as IEC 62304, one quality model tied to ISO 13485:2016, and one shared postmarket workflow for manufacturers and health delivery organizations.

Bottom line: if you wait for regulators to line up, you wait too long. The safer move is to build one internal model that can stand up in both markets.

Mastering EU and FDA Cybersecurity Requirements for Medical Devices

sbb-itb-535baee

Where Global Regulations Diverge Most

The gaps become easiest to spot in three places: software scope, cybersecurity, and evidence.

Differences in definitions, classifications, and software scope

The biggest divide is software scope. The same product can end up in different classes under the FDA and EU MDR. In the U.S., the FDA often leans on substantial equivalence through the 510(k) pathway. In Europe, EU MDR applies the more prescriptive Annex VIII rules.

Rule 11 is a major reason many software products move into higher-risk classes in Europe. If software provides information used to make decisions that could cause death or irreversible deterioration, EU MDR places it in Class III automatically. That creates a clear mismatch: the same product might be Class II in the U.S. but Class IIb or III in the EU. The day-to-day impact is simple: the EU path often takes longer for the same software.

The FDA also has specific exclusions under the 21st Century Cures Act for some clinical decision support (CDS) tools, administrative software, and low-risk wellness apps. EU MDR does not offer a matching carve-out. So a product that falls outside FDA device rules as a CDS exclusion can still land in Class IIa or higher under EU MDR Rule 11. For manufacturers, that usually means building two separate regulatory strategies for the same product.

Cybersecurity and software lifecycle requirements that do not match

Cybersecurity differs not just in detail, but in structure. The FDA created a legal category for "cyber devices," and that brings dedicated premarket requirements, including a Software Bill of Materials (SBOM) and structured threat modeling. EU MDR handles cybersecurity in a different way. It spreads those duties across all devices through the General Safety and Performance Requirements (GSPR) in Annex I, with no separate premarket cybersecurity gate.

The postmarket gap can create real exposure. Because EU MDR does not set fixed patching timelines, the same weakness may get fixed faster in the U.S. than in Europe. In plain English, devices in one region can stay exposed longer than the exact same devices somewhere else.

Inconsistent evidence, validation, and AI governance requirements

AI updates put the postmarket divide under a bright spotlight. Clinical evidence rules also split hard here. The FDA often accepts substantial equivalence to a predicate device without asking for new clinical data. EU MDR requires a full clinical evaluation for every device, applies heavy scrutiny to equivalence claims, and makes Post-Market Clinical Follow-up (PMCF) mandatory. If a manufacturer is going after both markets at once, it has to keep two different evidence packages moving on two different update cadences.

The FDA finalized its Predetermined Change Control Plan (PCCP) guidance for AI-enabled software in August 2025, giving manufacturers a set path to update AI/ML algorithms without triggering a new submission, as long as those changes were defined up front. Europe still has no matching path. Medical AI in Europe has to meet two overlapping frameworks: EU MDR for clinical safety and the EU AI Act for data governance and transparency. Core duties for high-risk AI systems apply from August 2, 2026 ^[1].

There’s another practical problem here: Notified Bodies are decentralized. That means Rule 11 and clinical evidence can be read a bit differently depending on the reviewer. So even when the written rule looks clear, the path in practice can shift from one review body to another, which makes a single global compliance plan much harder to pull off.

How Regulatory Gaps Affect Manufacturers and HDOs in Practice

These regulatory gaps create day-to-day operating problems. They slow product releases, repeat compliance work, and weaken postmarket control. So the issue isn’t just extra paperwork. It means slower updates and less visibility across the full device lifecycle.

Duplicated work, delayed updates, and inconsistent documentation

When a product is classified one way in one market and another way elsewhere, manufacturers can’t lean on a single validation package. They have to build separate evidence packages and run parallel documentation tracks.

The paperwork models add even more friction. FDA submissions are milestone-based and format-driven, including eSTAR. EU MDR calls for living technical documentation that stays current and ready for audit by Notified Bodies. For AI-enabled software, that often turns into two parallel tracks: one for clinical safety and another for data governance. Even a security patch can trigger a new review if it changes device identity or risk class.

When one patch sets off different duties by market, manufacturers need one internal process that can handle all of it, not a different process for each region. And these differences don’t stop once a product gets cleared. They keep shaping how updates, records, and ownership are handled after release.

How shared responsibility breaks down after deployment

After deployment, the biggest problem isn’t any single rule. It’s the split between manufacturer and HDO duties. On the manufacturer side, the FDA expects timely remediation tied to risk severity. Manufacturers also have to manage separate triage timelines and safety assessments.

HDOs run into their own version of the same mess. If the same physical device ships with different software versions across markets, keeping an accurate device inventory gets hard fast, especially when those versions were validated under different regional rules. That has a direct effect on patch validation and overall risk management.

The result is messy on the ground: hospitals end up dealing with incomplete inventories, uneven patch validation, and fragmented incident response. Neither side has the full risk picture, and the regulatory frameworks in place today don’t close that gap by themselves. So internal coordination becomes the only control teams can count on.

How to Self-Harmonize Across Global Requirements Today

Regulators aren't closing these gaps any time soon. So for now, internal harmonization is the only workable path. Global rules won't line up soon, which means manufacturers and HDOs need one internal control model that can hold up across markets.

Build a common internal framework for classification, SDLC, and evidence

Start with a shared language. Use the IMDRF SaMD framework as your common baseline for classification. It sorts software into four risk categories based on the clinical context and the way the software is used.

Next, build your SDLC around IEC 62304. It's recognized across markets, and its three safety classes - A, B, and C - let you scale documentation to fit device risk instead of treating every product the same. Pair that with ISO 13485, which now lines up the core quality system structure for both the U.S. and EU. The FDA's QMSR, effective February 2, 2026, incorporates ISO 13485:2016 by reference ^[1].

For AI-enabled software, the EU expects evidence mapping across both the MDR/IVDR and the AI Act at the same time. One path covers clinical safety. The other covers data governance and human oversight ^[1]. The smart move is to build that two-track structure into your SDLC from day one, instead of trying to bolt it on later. Technical documentation should work like a living record, with updates tied to every change.

You should also automate SBOM generation in CI/CD so inventories stay current. That supports FDA premarket needs and EU Cyber Resilience Act duties, which begin September 11, 2026 ^[1].

Standardize postmarket surveillance and shared security workflows

Once the framework is in place, align postmarket roles the same way in every market. A shared responsibility matrix helps split triage, patching, reporting, and SBOM upkeep between manufacturers and HDOs so there are fewer gray areas.

Use Censinet RiskOps™ to manage medical device software risk in one place

A centralized risk system makes this model easier to run at scale. Censinet RiskOps™ gives HDOs and vendors one system of record for device risk, remediation, and evidence tracking across teams.

Censinet AI™ speeds assessments by validating evidence, drafting policies, and summarizing vendor documentation automatically, while still keeping humans in the loop for final review and approval.

For AI governance, Censinet RiskOps™ also works as a central hub. It pulls real-time data into a dashboard that tracks AI-related policies, risks, and open tasks across the organization. It also assigns remediation tasks to the right owners, so oversight stays auditable and the program remains defensible.

Conclusion: Internal Harmonization Is the Answer to Fragmented Global Rules

Global medical device software rules are still fragmented. Regulators don't define software the same way, they set different cybersecurity duties, and they ask for different types of evidence for AI-enabled devices.

That said, the core building blocks are already on the table. ISO 13485:2016 sits underneath U.S. QMSR and EU quality systems. IEC 62304 brings order to the software lifecycle. And the IMDRF SaMD framework gives teams a shared language for classification. FDA QMSR, which took effect on February 2, 2026 ^[1], narrows the quality-system gap even more.

But shared standards don't remove the day-to-day work. Teams still need disciplined internal governance. The hard part is operational control: coordinating across different definitions, drawing clear lines around postmarket duties, and keeping technical documentation up to date as software changes.

In the EU, compliance isn't a one-time milestone. It's an ongoing operating practice. Organizations that do this well build internal control models that work across multiple markets and still hold up as rules shift. Centralized risk operations, shared responsibility, and automated evidence workflows are what make global compliance scale.

FAQs

Why can the same software be classified differently in the U.S. and EU?

The same medical device software can end up in different classes in the U.S. and the EU because each region uses a different system.

In the U.S., the FDA classifies software based on device product codes and whether it is substantially equivalent to a predicate device.

In the EU, the EU MDR uses a rules-based system, including rules such as Rule 11.

Those systems don’t match up neatly. So the exact same software can land in a higher or lower risk class depending on the jurisdiction.

What should companies standardize first for global compliance?

Start by standardizing the Quality Management System around ISO 13485. Then weave in design controls, risk management under ISO 14971, and post-market surveillance for software across the full lifecycle.

This shared backbone is where FDA and EU MDR line up most closely in intent, even if the proof you need to show - and the way each region handles review - differs.

How do AI updates affect FDA and EU approval paths?

In the U.S., the FDA handles AI updates through the Total Product Life Cycle framework, mainly with the Predetermined Change Control Plan (PCCP). In plain English, that means a manufacturer can spell out certain future changes in the first submission and get them cleared ahead of time. So when those pre-set updates happen later, the company usually doesn't need to file all over again.

In the EU, the path is tighter. Manufacturers have to meet both Medical Device Regulation and AI Act rules. And because there isn't a direct PCCP match, major design changes often trigger a new conformity assessment along with updated documentation.

Related Blog Posts

• FDA vs. EU MDR: Medical Device Patching Rules
• FDA Cybersecurity Guidance: Medical Device Reporting Rules
• Interoperability vs. Security: Balancing FDA Standards
• Regulatory Frameworks for IoT in Healthcare